Skip to main content

TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Tue Jun 17, 2025

TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $8.50. The company’s shares closed today at $9.07.

Confident Investing Starts Here:

Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Neurogene. According to TipRanks, Baral has an average return of 7.3% and a 46.40% success rate on recommended stocks.

SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.75, representing a -3.53% downside. In a report released today, Wedbush also maintained a Hold rating on the stock with a $8.50 price target.

See today’s best-performing stocks on TipRanks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.06 million and a GAAP net loss of $62.21 million. In comparison, last year the company earned a revenue of $7.9 million and had a GAAP net loss of $108.48 million

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).